Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest InSightec Ltd. Stories

2010-08-31 00:59:00

TIRAT CARMEL, Israel, August 31, 2010 /PRNewswire/ -- InSightec Ltd., the global leader in MR guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate(R) system for treating uterine fibroids, announced today that its ExAblate(R) system has been used for the first time for the treatment of prostate cancer patients. Seven patients with localized low-risk prostate cancer were treated worldwide so far. The patients were treated at two leading medical...

2010-08-31 00:37:00

TEL AVIV, Israel, August 31, 2010 /PRNewswire-FirstCall/ -- - ExAblate(R) MR Guided Focused Ultrasound System is Being Used for the First Time for Non-invasive Treatment of Prostate Cancer - Seven Patients With Prostate Confined Low Risk Cancer Treated in Clinical Trials Elbit Imaging Ltd. (NASDAQ: EMITF) ("Elbit" "Company") that it's subsidiary, InSightec Ltd., the global leader in MR guided focused ultrasound technology and the only company to receive FDA approval for its...

2010-01-14 03:01:00

TEL AVIV, January 14 /PRNewswire-FirstCall/ -- Elbit Imaging Ltd. (NASDAQ: EMITF) ("Elbit" "Company") that its subsidiary, InSightec Ltd., announced today that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the company's ExAblate(R) MR-guided Focused Ultrasound (MRgFUS) system for the treatment of women with uterine fibroids. ExAblate is currently the only noninvasive treatment for uterine fibroids approved for use in Japan. InSightec Ltd. estimates that...

2010-01-13 08:00:00

TIRAT CARMEL, Israel, January 13 /PRNewswire/ -- - InSightec's ExAblate System Uses Magnetic Resonance-guided Focused Ultrasound to Perform Uterine Procedures Without Incisions InSightec Ltd. announced today that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the company's ExAblate(R) MR-guided Focused Ultrasound (MRgFUS) system for the treatment of women with uterine fibroids. "We are very pleased that the Japanese Ministry of Health has approved the...

2009-11-11 07:00:00

TIRAT CARMEL, Israel, November 11 /PRNewswire/ -- InSightec Ltd. today announced that three new papers published in the November issue of Ultrasound in Obstetrics and Gynecology add to the growing body of data supporting the use of ExAblate(R) as a safe, effective and durable treatment for uterine fibroids. One study showed that non-invasive treatment with the ExAblate Magnetic Resonance-guided Focused Ultrasound (MRgFUS) system offers women a significantly less risky treatment for...

2009-04-07 07:00:00

TIRAT CARMEL, Israel, April 7 /PRNewswire/ -- InSightec Ltd. announced today that the U.S. Food and Drug Administration (FDA) approved a label change for the company's ExAblate(R) 2000 MR-guided Focused Ultrasound (MRgFUS) system for the treatment of women with non-hysteroscopically resectable uterine fibroids. Under the new labeling, the agency allows physicians to treat up to 100% of the fibroid compared to its previous restriction to only treat up to half the fibroid tissue. "In...

2009-03-19 04:14:00

TIRAT CARMEL, Israel, March 19 /PRNewswire/ -- InSightec Ltd. reported today that it has closed an internal round of financing totaling US$15 million from its existing investors. Elbit Imaging Ltd. (NASDAQ: EMITF) ("EI") has invested US$7.5M on March 18, 2009. Additional US$7.5M would be invested no later than 12 months following the date hereof by its existing investors. The investment will take the form of Preferred Shares B, which are convertible to InSightec's ordinary...

2008-12-16 07:00:00

TIRAT CARMEL, Israel, December 16 /PRNewswire/ -- InSightec Ltd. announced today that cancer patients suffering pain caused by tumors that have spread to their bones have a new online resource for information about their condition. The website, http://www.MyCancerPain.org, provides background on bone metastases, as well as detailed information about a clinical trial being conducted at eleven centers in the U.S., Canada and Israel to evaluate whether treatment with the noninvasive,...

2008-12-02 07:00:00

TIRAT CARMEL, Israel, December 2 /PRNewswire/ -- InSightec Ltd. announced today that new publications show that Magnetic Resonance-guided Focused Ultrasound (MRgFUS) with the ExAblate(R) system has the potential to be an effective noninvasive pain-relieving treatment for tumors that have spread to the bones (bone metastases). The results of a 31 patient study appear in the November 11 online issue of Annals of Surgical Oncology, while data from an eleven-patient subgroup analysis of that...